Amyloid Experts Predict the Most Transformative Advances Coming Soon in Cardiac Amyloidosis

For the latest episode of the JNC CardioConnect podcast, Marcelo F. Di Carli, MD, MASNC, brought together 4 experts for a conversation about where the field of cardiac amyloidosis stands today, the potential of forthcoming innovations, and where the truly transformative opportunities lie. The podcast was inspired by the new open-access JNC Compendium: Cardiac Amyloidosis – Pathophysiology, Imaging, and Contemporary Management.

Episode 14 of the JNC CardioConnect podcast highlights research from the new JNC Compendium: Cardiac Amyloidosis – Pathophysiology, Imaging, and Contemporary Management. Row 1, from left: Omar F. Abou Ezzeddine, MD, MS, Marcelo F. Di Carli, MD, MASNC, and Ahmad Masri, MD, MS. Row 2, from left: Prem Soman, MD, PhD, MASNC, and Sharmila Dorbala, MD, MPH, MASNC.

Omar F. Abou Ezzeddine, MD, MS, Sharmila Dorbala, MD, MPH, MASNC, Ahmad Masri, MD, MS, and Prem Soman, MD, PhD, MASNC, each take a turn sharing key points from their work featured in the compendium, emphasizing current best practices and takeaways for clinical practice. They address the biology that explains what is seen on current imaging; best practices in cardiac amyloid radionuclide scintigraphy; the promise of amyloid-targeted PET radiotracers; emerging novel therapies; and the roles that imaging is poised to play in monitoring disease, assessing treatment response, and guiding therapeutic decision-making.

Be sure to stay for the final few minutes. Dr. Di Carli throws out a lightning round, challenging each guest to look just 3-5 years into the future and select the single advance that would most transform the field. Their answers may surprise you – and they may spark ideas of your own.

Listen Now